Martina Hansens Hospital, P.O. Box 23, 1306 Baerum Postterminal, Norway.
Clin Orthop Relat Res. 2012 Sep;470(9):2591-8. doi: 10.1007/s11999-012-2320-9. Epub 2012 Apr 3.
Thrombin formation commences perioperatively in orthopaedic surgery and therefore some surgeons prefer preoperative initiation of pharmacologic thromboprophylaxis. However, because of the potential for increased surgical bleeding, the postoperative initiation of thromboprophylaxis has been advocated to reduce blood loss, need for transfusion, and bleeding complications. Trials on timing of thromboprophylaxis have been designed primarily to detect thrombotic events, and it has been difficult to interpret the magnitude of blood loss and bleeding events owing to lack of information for bleeding volume and underpowered bleeding end points.
QUESTIONS/PURPOSES: We therefore asked whether there are differences in blood loss, transfusion requirements, and other postoperative clinical complications with preoperative versus postoperative start of thromboprophylaxis with dalteparin.
In a double-blind, randomized controlled trial, 80 patients undergoing primary cemented THA were allocated to dalteparin injections starting 12 hours before or 6 hours after surgery. Blood loss was measured by weighing sponges and drapes, volume in suction drains during surgery, and wound drains until removal 24 hours postoperatively. Hemoglobin and hematocrit were recorded at predefined times during and after surgery.
We found no differences in blood loss (1081 mL ± 424 mL versus 1023 mL ± 238 mL), bleeding-related events (10% versus 17%), or number of patients who had transfusions (12 versus five) with preoperative and postoperative thromboprophylaxis, respectively. Other complications were few in both groups.
Our data suggest blood loss is similar with preoperative and postoperative initiation of dalteparin thromboprophylaxis, but indicate a trend toward fewer transfusion requirements which might favor postoperative start of thromboprophylaxis.
在骨科手术中,凝血酶的形成始于围手术期,因此一些外科医生更喜欢术前开始使用药物预防血栓形成。然而,由于手术出血增加的风险,术后开始血栓预防已被提倡以减少失血、输血需求和出血并发症。关于血栓预防时机的试验主要旨在检测血栓形成事件,由于缺乏出血量信息和出血终点数据不足,很难解释失血和出血事件的严重程度。
问题/目的:因此,我们想知道在接受达肝素预防性抗凝治疗时,与术前开始相比,术后开始是否会导致出血量、输血需求和其他术后临床并发症的差异。
在一项双盲、随机对照试验中,80 例接受初次骨水泥型全髋关节置换术的患者被分配至达肝素注射组,分别于术前 12 小时或术后 6 小时开始用药。通过称重纱布和手术巾、术中吸引器引流管中的体积以及术后 24 小时内伤口引流管中的体积来测量出血量。血红蛋白和血细胞比容在手术期间和之后的预定时间记录。
我们发现术前和术后开始达肝素预防性抗凝治疗在出血量(1081 毫升±424 毫升比 1023 毫升±238 毫升)、与出血相关的事件(10%比 17%)或需要输血的患者人数(12 例比 5 例)方面均无差异。两组其他并发症均较少。
我们的数据表明,术前和术后开始使用达肝素预防血栓形成的出血量相似,但术后开始的输血需求似乎更少,这可能更倾向于术后开始预防血栓形成。